Abstract
Background Liver fat is associated with cardiometabolic disease, cerebrovascular disease, and dementia. Cerebrovascular disease, most frequently cerebral small vessel disease, identified by MRI as white matter hyperintensities (WMH), often contributes to dementia. However, liver fat’s role in the relationship between cardiometabolic risk, WMH, and cognitive performance is unclear.
Methods In the UK Biobank cohort (n=32,628; 52.6% female; mean age 64.2±7.7 years; n=23,467 cognitive performance subsample), we used linear regression to investigate associations between cardiometabolic factors measured at baseline and liver fat, WMH, and cognitive performance measured at follow-up, on average, 9.3±2.0 years later. We used structural equation modeling to investigate whether liver fat mediates associations between cardiometabolic factors and WMH and whether WMH mediates associations between liver fat and cognitive performance.
Results Nearly all cardiometabolic factors were significantly associated with liver fat (|r| in [0.03,0.41], p in [1.4x10-8,0〉) and WMH (|r| in [0.05,0.14], p in [1.5x10-13,2.7x10-148]) in regression models. Liver fat was associated with WMH (r=0.09,p=3x10-64) and cognitive performance (r=-0.03,p=1.5x10-7). Liver fat mediated the associations between cardiometabolic factors and WMH (|βmediation| in [0.01,0.03], pmediation in [5.7x10-9,0〉) and WMH mediated the associations between liver fat and cognitive performance (βmediation=-0.01,pmediation≍0).
Conclusions Our findings indicate that liver fat mediates associations between cardiometabolic factors and WMH and that WMH mediates the association between liver fat and cognitive performance. This suggests that liver fat might be important for understanding the effects of cardiometabolic factors on cerebrovascular disease and cognitive function. Experimental studies are warranted to determine relevant targets for preventing vascular-driven cognitive impairment.
Competing Interest Statement
OAA has received a speaker's honorarium from Lundbeck, Sunovion, Otsuka, and Janssen and is a consultant to Cortechs.ai. PA is employed by AMRA Medical AB. The remaining authors declare no conflict of interest.
Funding Statement
This project has received funding from the South-Eastern Norway Regional Health Authority (#2022080), the European Union’s Horizon 2020 Research and Innovation Programme (CoMorMent project #802998), the Research Council of Norway (#223273), the German Federal Ministry of Education and Research (BMBF, #01ZX1904A), the European Research Council (ERC) StG (Grant #802998), and the European Union for the Horizon Europe project ’environMENTAL’ (#1010576429), with complementary funding from the UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee (10041392 and 10038599).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank obtained informed consent from all participants, has IRB approval from the North West Multi-center Research Ethics Committee, and the Ethics Advisory Committee (https://www.ukbiobank.ac.uk/ethics) oversees the UK Biobank Ethics and Governance Framework. We obtained access to the UK Biobank cohort through Application number 27412. We have approval from the Regional Committees for Medical and Health Research Ethics in Norway.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
